Meeting
2018 Genitourinary Cancers Symposium
A phase I/II study of sitravatinib (MGCD-516) plus nivolumab in patients (pts) with metastatic clear-cell renal cell carcinoma (ccRCC) that progressed on prior VEGF-targeted therapy.
Authors
Pavlos Msaouel
UT MD Anderson Cancer Center, Houston, TX
Pavlos Msaouel , Peter F. Thall , Ying Yuan , Isan Chen , Nizar M. Tannir
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT03015740
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr TPS708)
DOI
10.1200/JCO.2018.36.6_suppl.TPS708
Abstract #
TPS708
Poster Bd #
L15
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Overall survival, efficacy, and safety outcomes beyond front-line modern therapies in metastatic clear-cell renal cell carcinoma.
First Author: Jordyn Kreutzfeldt
Poster
2022 ASCO Genitourinary Cancers Symposium
The impact of baseline peripheral cytokines on survival in metastatic clear cell renal cell carcinoma (RCC) treated with nivolumab: NIVOREN GETUG-AFU 26 Translational study.
First Author: Lucia Carril
Poster
2021 Genitourinary Cancers Symposium
Phase I/IB trial of sitravatinib (Sitra) + nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC) or other solid malignancies.
First Author: Pavlos Msaouel
Poster
2020 ASCO Virtual Scientific Program
A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma.
First Author: Elizabeth Iannotti Buchbinder